The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles

CONCLUSIONS: Phosphopeptides presented by multiple alleles that are differentially expressed on tumors constitute tumor-specific antigens that could be targeted for cancer immunotherapy, but the immunogenicity of such phosphopeptides is not a general feature. In particular, phosphopeptides presented by HLA-A02:01 and A11:01 exhibit consistent immunogenicity, while phosphopeptides presented by HLA-A03:01 and C07:01, although appropriately presented, are not immunogenic. Thus, to address …